Schering AG Making Oncology A Primary Focus; Dermatology Unit Will Become Separate Entity

Berlex’ German parent says the new focus will help it exploit the potential of a Phase III angiogenesis inhibitor under development with Novartis. Portfolio restructuring includes termination of R&D in cardiovascular and CNS areas, except for multiple sclerosis and Parkinson’s disease.